Display options
Cite
Lupo S, Berini C, Cánepa C, et al. Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report. Front Oncol. 2017;7:91doi: 10.3389/fonc.2017.00091.
Lupo, S., Berini, C., Cánepa, C., Santini Araujo, E., & Biglione, M. (2017). Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report. Frontiers in oncology, 791. https://doi.org/10.3389/fonc.2017.00091
Lupo, Sergio, et al. "Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report." Frontiers in oncology vol. 7 (2017): 91. doi: https://doi.org/10.3389/fonc.2017.00091
Lupo S, Berini C, Cánepa C, Santini Araujo E, Biglione M. Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report. Front Oncol. 2017 May 24;7:91. doi: 10.3389/fonc.2017.00091. eCollection 2017. PMID: 28596939; PMCID: PMC5442215.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2017 May 24;7:91. doi: 10.3389/fonc.2017.00091. eCollection 2017.

Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report.

Frontiers in oncology

Sergio Lupo, Carolina Berini, Camila Cánepa, Eduardo Santini Araujo, Mirna Biglione

Affiliations

  1. School of Medical Sciences (UNR) and UAI Rosario, Centralized Institute of Integral Clinical Research (CAICI), Rosario, Argentina.
  2. CONICET-Universidad de Buenos Aires, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Buenos Aires, Argentina.
  3. Laboratory of Orthopaedic Pathology, Buenos Aires, Argentina.

PMID: 28596939 PMCID: PMC5442215 DOI: 10.3389/fonc.2017.00091

Abstract

INTRODUCTION: Soft-tissue sarcomas account for 0.7% of all malignant tumors, with an incidence rate of 3 per 100,000 persons/year. The undifferentiated pleomorphic sarcoma (UPS) with giant cells, a high grade tumor of soft tissue, is very unusual, especially in young adults before the age of 40. Human T-cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus, classified as group 1 human carcinogens by The International Agency for Research on Cancer, that causes an aggressive malignancy known as adult T-cell lymphoma/leukemia and a progressive chronic inflammatory neurological disease named HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 causes accumulation of genetic mutations in the host genome that could contribute to cellular transformation, one of the oncogenic features of HTLV-1.

CASE REPORT: We describe a case of a young woman with UPS who suffered from HAM/TSP with 3 years of evolution. In 2013, the patient started with neurological symptoms: weakness in the legs and bladder dysfunction. One year later, the patient developed a mild paraparesis in both extremities, anti-HTLV-1 antibodies were detected in plasma and in cerebrospinal fluid, and HAM/TSP was confirmed. In November 2015, a benign ganglion cyst was first suspected without intervention and by March 2016 a sarcoma was diagnosed. Three weeks after surgical resection, the tumor aroused in deep tissue and behaved aggressively, implicating a curative wide resection of the fibula, joint reconstruction, and soft-tissue graft. Histopathological examination confirmed UPS with giant cells.

CONCLUDING REMARKS: The unapparent subclinical immunodeficiency state due to HTLV-1 infection deserves to be considered in order to carefully monitor the possibility of developing any type of cancer. Besides, reaching an accurate and timely diagnosis of UPS can be challenging due to the difficulty in diagnosis/classification and delayed consultation. In this particular case, considering the high grade of UPS and the progressive invalidating myelopathy caused by HTLV-1, treatment should be carefully evaluated to positively impact on the patient's life expectancy.

Keywords: HTLV-1; immunodeficiency; mutation; myelolpathy; sarcoma

References

  1. Int J Exp Pathol. 2001 Jun;82(3):135-47 - PubMed
  2. J Cell Biochem. 1991 Aug;46(4):302-11 - PubMed
  3. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 - PubMed
  4. J Virol Methods. 1992 Nov;40(2):163-73 - PubMed
  5. PLoS One. 2015 Jan 08;10(1):e0115672 - PubMed
  6. J Clin Pathol. 2007 Dec;60(12):1373-7 - PubMed
  7. Cancer. 1988 Dec 1;62(11):2330-40 - PubMed
  8. Bull Cancer. 2010 Nov;97(11):1337-45 - PubMed
  9. Sex Transm Infect. 2013 Jun;89(4):333-5 - PubMed
  10. Front Microbiol. 2012 Nov 15;3:388 - PubMed
  11. Histopathology. 2014 Jan;64(1):2-11 - PubMed
  12. Oncol Res. 2013;20(9):403-10 - PubMed
  13. Int J Clin Exp Pathol. 2015 Jul 01;8(7):8563-7 - PubMed
  14. Science. 2004 Apr 23;304(5670):554 - PubMed
  15. Int J Oncol. 2009 Oct;35(4):701-7 - PubMed
  16. Viruses. 2015 Oct 28;7(11):5643-58 - PubMed
  17. Lancet Oncol. 2014 Apr;15(4):415-23 - PubMed
  18. Recent Results Cancer Res. 2014;193:11-32 - PubMed
  19. J Cancer Sci. 2015 Sep;2(2):null - PubMed

Publication Types